With Antisense Rx Already in Phase I, Bio-Path Eyes RNAi Rx Market

The company hopes phase I data from the antisense candidate will confirm the efficacy of its proprietary delivery technology and help it secure capital and biopharma partnerships to advance an siRNA-based cancer therapeutic into the clinic.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.